Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX ® (cabozantinib) in Combination with Opdivo ® (nivolumab) in Patients with Advanced Kidney Cancer at
Source link
Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX ® (cabozantinib) in Combination with Opdivo ® (nivolumab) in Patients with Advanced Kidney Cancer at
By Bella Hayes
